Medicinova, Inc. · NASDAQ:MNOV
Medicinova — Investor Presentation (October 2010)
9 slides from Medicinova's investor presentation, Oct 4, 2010
Slide 1: Accelerating the global development and commercialization of innovative pharmaceuticals
Accelerating the global development and commercialization of innovative pharmaceuticals © MediciNova, Inc. 2010 Exhibit 99.1
Slide 2: Forward-Looking Statements
© MediciNova, Inc. 2010 Forward-Looking Statements Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forwar
Slide 3: Corporate Overview: MediciNova
© MediciNova, Inc. 2010 MediciNova Overview: • Founded in September 2000 • Headquartered in San Diego, CA • Additional office in Tokyo, Japan • Dual-listing on NasdaqGM as MNOV and Osaka Securities Exchange as 4875 • $63.3 million Market Cap (NasdaqGM) as of 9/28/2010 Development Company Focused on
Slide 4: Business Model
Business Model Business Model In-License therapeutic small molecules from Japan to develop in US/EU for global markets In-License: Product candidates with significant clinical or preclinical data Development: Conduct Proof-of Concept (Phase I and Phase II) clinical trials Two Pathways to ROI: 1. Con
Slide 5: Why Japan?
Why Japan? Why Japan? • Recent Japanese pharma blockbusters • Mid-size pharma firms generally must partner to reach global markets • Opportunity for US/global developer that understands Japan • Need for globalization by Japanese Pharma as market lags behind USA and European markets *PharmaLive Speci
Slide 6: History: Portfolio building based on In-licensing
© MediciNova, Inc. 2010 History : Portfolio building based History : Portfolio building based on In-licensing on In-licensing • Sep. 2000 Incorporated MediciNova, Inc. in San Diego, CA • June 2001 Initiated research collaboration with Institute of Medical Sciences at University of Tokyo • Mar. 2002
Slide 7: Commercially-Attractive Diversified Portfolio
Commercially-Attractive Commercially-Attractive Diversified Portfolio Diversified Portfolio Stage of development when licensed: Work completed by MediciNova (MNOV) since in-license: © MediciNova, Inc. 2010
Slide 8: MediciNova
MEDICINOVA
Slide 9: On-going Clinical Activity and Current Strategy
© MediciNova, Inc. 2010 On-going Clinical Activity: 1. MN-221-CL-007 Phase II Study for Acute Exacerbations of Asthma • Anticipated completion 1Q, 2011* 2. MN-166 Study for Opioid Withdrawal • Anticipated completion in 2H, 2010* Potential upcoming Business Deals: 1. Secure a global partnership for M